LDL Cholesterol

A Critical Question

Treatment → Adherence → Outcomes

LDL-C Reduction and Platelet Activity in At-Risk Patients With Dyslipidemia

Percent Change From Baseline to Week 24 in LDL-C Alirocumab vs Placebo

LDL-C Reduction and Improvement in Left Ventricular Function

Safety Concerns With Very Low Levels of LDL-C

Inclusion Criteria FOURIER and ODYSSEY Outcomes

PCSK9 Inhibitors in the Acute Care Setting

Summary and Conclusions

Acute Coronary Syndromes and LDL Cholesterol

Introduction/Overview

Some Mechanisms in the Etiology of ACS

Results ODYSSEY OUTCOMES Trial

Secondary Prevention in Patients at Very High ASCVD Risk: AHA/ACC Cholesterol Management Guidelines

GLAGOV Trial Results Change in Percent Atheroma Volume

Ezetimibe IMPROVE-IT Results

Adverse Events FOURIER Evolocumab vs Placebo

Some Problems With Statins Some Patients Don't Respond, Others Can't Tolerate

Lowering LDL-C as Much as Possible and as Rapidly as Possible

FOURIER Cumulative Incidence of CV Events

FOURIER (Evolocumab) Baseline Characteristics

ODYSSEY OUTCOMES Event Rates Alirocumab vs Placebo

Patients in FOURIER Achieved Very Low LDL-C Levels, Without Harm and With CV Benefit

Early Introduction of Lipid-Lowering Therapy Post-ACS

Summary and Conclusions

Abbreviations